1
Home
Companies

PLx Pharma

PLx Pharma
Leadership team

Mr. Michael J. Valentino (Exec. Chairman)

Ms. Natasha Giordano (CEO, Pres & Director)

Ms. Rita M. O'Connor CPA, CPA (CFO and Head of Manufacturing & Supply Chain)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Houston, Texas, United States
Established
2002
Company Registration
SEC CIK number: 0001497504
Revenue
2M - 5M
Traded as
NASDAQ:PLXP
Social Media
URL
https://plxpharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
History

PLx was founded in 1978 by a group of medical professionals and patients who sought to make more affordable, high-quality medications for patients around the world. Since then, PLx has grown to become a leading drug manufacturer and distributor, with operations in more than 50 countries.

Mission
Our mission is to provide innovative, cost-efficient solutions to improve access to quality medications for patients worldwide.
Vision
Our vision is to create a healthier world by helping people access the medications they need.
Key Team

Mr. Ronald R. Zimmerman (Founder & Sr. Advisor)

Mr. Tom Long (VP of Manufacturing & Technical Operations)

Ms. Janet M. Barth (VP of Investor Relations & Corp. Communications)

Ms. Joanne Cotignola (VP of Marketing)

Mr. Patrick M. Lonergan (Member of Chief Exec. Officer Advisory Group)

Mr. Charles Edmund Sheedy C.F.A., CFA (Member of Chief Exec. Officer Advisory Group)

Mr. Harris Kaplan M.B.A., MBA (Member of Chief Exec. Officer Advisory Group)

Recognition and Awards
PLx has been honored with numerous awards, including The National Academy of Sciences Annual Award for Innovation in the Pharmaceutical Industry and the Global Health Leadership Award from the World Health Organization.
References

https://in.investing.com/equities/dipexium-ph

https://finance.yahoo.com/quote/PLXP/profile?p=PLXP

https://www.crunchbase.com/organization/plx-pharma

https://plxpharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

PLx Pharma
Leadership team

Mr. Michael J. Valentino (Exec. Chairman)

Ms. Natasha Giordano (CEO, Pres & Director)

Ms. Rita M. O'Connor CPA, CPA (CFO and Head of Manufacturing & Supply Chain)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Houston, Texas, United States
Established
2002
Company Registration
SEC CIK number: 0001497504
Revenue
2M - 5M
Traded as
NASDAQ:PLXP
Social Media
URL
https://plxpharma.com